- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Metabolome.
Displaying page 1 of 1.
EudraCT Number: 2018-000003-16 | Sponsor Protocol Number: UPBEAT-TIF | Start Date*: 2018-11-06 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Prevention of Gestational Diabetes in Obese Pregnant Women; a Proof of Principle Study Targeting Early Pregnancy Intervention to Women at Risk | |||||||||||||
Medical condition: Gestational diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003817-32 | Sponsor Protocol Number: LOLA-Merz:WMDHP39937 | Start Date*: 2013-01-08 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate | |||||||||||||
Medical condition: Hepatic Encephalopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004011-44 | Sponsor Protocol Number: UofATURRIFIC | Start Date*: 2020-05-20 |
Sponsor Name:The University of Adelaide | ||
Full Title: A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruri... | ||
Medical condition: Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main symptom of this is itching. Ursodeoxycholic acid is routinely used to treat cholestasis but is not... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006224-40 | Sponsor Protocol Number: AxGD | Start Date*: Information not available in EudraCT |
Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka" | ||
Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p... | ||
Medical condition: Gaucher disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004842-40 | Sponsor Protocol Number: IG1309 | Start Date*: 2014-05-09 | |||||||||||
Sponsor Name:Instituto Grifols S.A. | |||||||||||||
Full Title: Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis | |||||||||||||
Medical condition: Amytrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001696-79 | Sponsor Protocol Number: KH176-201 | Start Date*: 2016-09-06 |
Sponsor Name:Khondrion BV | ||
Full Title: A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitoc... | ||
Medical condition: Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005059-10 | Sponsor Protocol Number: Trp-IBD | Start Date*: 2018-09-14 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores | ||
Medical condition: Inflammatory Bowel Disease (IBD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004010-19 | Sponsor Protocol Number: IMEA064 | Start Date*: 2021-10-15 |
Sponsor Name:IMEA-Fondation Léon M'Ba | ||
Full Title: Pharmacokinetics of calcineurin & mTOR inhibitors in HIV-1 infected kidney transplant recipients after switch to BIC/FTC/TAF: a pilot study - KINETIK (KIdNEy Transplant bIKtarvy) IMEA 064 | ||
Medical condition: • HIV-1 infected patients > 18 years • Antiretroviral treatment switch to BIC/FTC/TAF decided in standard care by ID physician • Kidney transplant recipient ≥ 3 months • Receiving calcineurin and/o... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002795-13 | Sponsor Protocol Number: TACRO-Omics | Start Date*: 2020-04-23 |
Sponsor Name:Fundación de Investigación Hospital Universitario La Paz | ||
Full Title: Identification of "omic" biomarkers and their inter and intra-individual variability that allow improvement in the individualization of tacrolimus: uncontrolled clinical trial in pediatric patients... | ||
Medical condition: Pediatric patients with renal transplantation (under stable treatment with tacrolimus as immunosuppressant) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005753-12 | Sponsor Protocol Number: RG_15-026 | Start Date*: 2017-11-22 |
Sponsor Name:University of Birmingham | ||
Full Title: Prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis. | ||
Medical condition: Ulcerative colitis for at least 3 months prior to trial entry | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004418-17 | Sponsor Protocol Number: I-BCT-1 | Start Date*: 2014-05-07 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens. | ||
Medical condition: breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003760-27 | Sponsor Protocol Number: INCENTIVE-QIV-3-EU | Start Date*: 2021-09-21 |
Sponsor Name:Université Libre de Bruxelles | ||
Full Title: INCENTIVE-QIV-3-EU: Immunogenicity, molecular profiling of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra®) administered by the intramuscular route in participants aged 6 to 8 months | ||
Medical condition: Prophylaxis of Influenza (Northern Hemispher 2021-2022 and 2022-2023 season) in Children aged 6-8 months | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006487-24 | Sponsor Protocol Number: ADNorGC | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Helse Bergen HF | |||||||||||||
Full Title: A registry-based, open-label, randomized study to investigate quality-of-life with Plenadren compared with Cortison in participants aged 16-80 with newly diagnosed primary adrenal insufficiency | |||||||||||||
Medical condition: Primary adrenal insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002838-20 | Sponsor Protocol Number: NL.45391.018.13 | Start Date*: 2013-11-12 | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: The effect of Vitamin D3 to prevent post-operative relapse of Crohn’s Disease: a placebo-controlled randomized trial (DETECT) | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001056-55 | Sponsor Protocol Number: INCLASS | Start Date*: 2017-08-28 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL STUDY OF THE EFFICACY OF INTRAVENOUS CLARITHROMYCIN AS ADJUNCTIVE TREATMENT IN PATIENTS WITH SEPSIS AND RESPIRATORY AND MULTIPLE ORGAN DYSFUN... | |||||||||||||
Medical condition: IMMUNE MODULATION WITH CLARITHROMYCIN IN SEPSIS WITH MULTIPLE ORGAN AND RESPIRATORY DYSFUNCTION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003429-32 | Sponsor Protocol Number: ImbruVeRCHOP-Trial | Start Date*: 2017-02-09 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2” | ||
Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001625-16 | Sponsor Protocol Number: PBI-4050-ATX-9-05 | Start Date*: 2015-10-29 | |||||||||||
Sponsor Name:ProMetic BioSciences Inc. | |||||||||||||
Full Title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström... | |||||||||||||
Medical condition: Alström Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001772-11 | Sponsor Protocol Number: OXN2505 | Start Date*: 2014-01-23 | |||||||||||
Sponsor Name:Mundipharma Research GmbH & Co. KG | |||||||||||||
Full Title: An exploratory, double-blind, double-dummy, randomised, 2-period, crossover, Phase IIa study to assess the influence of oxycodone/naloxone prolonged-release tablets (OXN PR) and oxycodone prolonged... | |||||||||||||
Medical condition: The intended indication is: Chronic severe non malignant pain, requiring opioids. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004824-77 | Sponsor Protocol Number: 27UCS2015 | Start Date*: 2016-06-23 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal ... | |||||||||||||
Medical condition: Surgical resected colorectal cancer (stage I-III) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
